A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users

Hepatology

Volumn 57, Issue 3, 2013, Pages 944-952

  Kim, Arthur Y ^a,b   Nagami, Ellen H ^a,b,c,d   Birch, Christopher E ^a,b,d   Bowen, Melinda J ^a,f   Lauer, Georg M ^a   McGovern, Barbara H ^d,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d LEMUEL SHATTUCK HOSPITAL   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG USE; ETHNICITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; VIRUS IDENTIFICATION;

ACUTE DISEASE; ADULT; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; PRISONERS; PROGRAM EVALUATION; RISK FACTORS; SELF REPORT; SEROEPIDEMIOLOGIC STUDIES; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84874472433     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26113     Document Type: Article

References (45)

1. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. HEPATOLOGY 2001; 34: 180-187.
2. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099-1109.
3. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011; 171: 242-248.
4. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40(Suppl. 5): S276-S285.
5. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121: 710-719.
6. Weinbaum C, Lyerla R, Margolis HS. Prevention and control of infections with hepatitis viruses in correctional settings. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52: 1-36.
7. Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis 2005; 41: 177-186.
8. Bureau of Justice. http://bjs.ojp.usdoj.gov/index.cfm?ty=pbdetail&iid=2056, 2011. Accessed May 30, 2012.
9. Spaulding A, Greene C, Davidson K, Schneidermann M, Rich J. Hepatitis C in state correctional facilities. Prev Med 1999; 28: 92-100.
10. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington, DC: National Academies Press; 2010.
11. McGovern BH, Wurcel A, Kim AY, Schulze Zur Wiesch J, Bica I, Zaman MT, et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 2006; 42: 1663-1670.
12. Thomas DL. Acute hepatitis C: a window of opportunity. Clin Infect Dis 2006; 42: 1671-1673.
13. Massachusetts Department of Correction Research and Planning Division. 2007 Court Commitments to the Massachusetts Department of Correction, Publication No. 08-133-03, 2008.
14. Hagan H, Pouget ER, Williams IT, Garfein RL, Strathdee SA, Hudson SM, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis 2010; 201: 378-385.
15. McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009; 49: 1051-1060.
16. Wasley A, Miller JT, Finelli L. Surveillance for Acute Viral Hepatitis-United States, 2005. MMWR 2007; 56: 1-24.
17. McGovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, et al. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200: 877-881.
18. Cox AL, Page K, Bruneau J, Shoukry NH, Lauer GM, Kim AY, et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009; 136: 26-31.
19. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-46.
20. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
21. Centers for Disease Control and Prevention. Hepatitis C virus infection among adolescents and young adults-Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep 2011; 60: 537-541.
22. Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA 2012; 307: 1259-1260.
23. Sabol WJ. Prisoners in 2008. Bureau of Justice Statistics; 2009.
24. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59: 1-111.
25. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005; 19(Suppl 3): S20-S25.
26. Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend 2008; 94: 221-233.
27. Lelutiu-Weinberger C, Pouget ER, Des Jarlais DD, Cooper HL, Scheinmann R, Stern R, et al. A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups. Soc Sci Med 2009; 68: 579-590.
28. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings Office of Applied Studies, NSDUH Series H-38A, Department of Health and Human Services Publication No. SMA 10-4586 Findings; 2010.
29. Notes from the field: hepatitis C virus infections among young adults-rural Wisconsin, 2010. MMWR Morb Mortal Wkly Rep 2012; 61: 358.
30. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204: 74-83.
31. Eastman E, Rappaport E, DeMaria A, Werner B. Validation of self-reported risk as a method for identifying anti-hepatitis C positive individuals at time of intake physical examination at Massachusetts Department of Correction facilities. In: 129th Annual Meeting of the American Public Health Association; October 21-25, 2001; Atlanta, GA.
32. Calzavara L, Ramuscak N, Burchell AN, Swantee C, Myers T, Ford P, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities. CMAJ 2007; 177: 257-261.
33. Poulin C, Alary M, Lambert G, Godin G, Landry S, Gagnon H, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Quebec provincial prisons. CMAJ 2007; 177: 252-256.
34. Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D. Gender differences in the initiation of injection drug use among young adults. J Urban Health 2000; 77: 396-414.
35. Boutwell AE, Allen SA, Rich JD. Opportunities to address the hepatitis C epidemic in the correctional setting. Clin Infect Dis 2005; 40(Suppl. 5): S367-S372.
36. Centers for Disease Control and Prevention. http://www.cdc.gov/hepatitis/PDFs/disease_burden.pdf. Accessed July 7, 2011.
37. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005; 40: 951-958.
38. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372: 321-332.
39. Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat 2010; 17: 201-207.
40. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-573.
41. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med 2011; 364: 2429-2438.
42. Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. J Hepatol 2009; 51: 628-631.
43. Macalino GE, Dhawan D, Rich JD. A missed opportunity: hepatitis C screening of prisoners. Am J Public Health 2005; 95: 1739-1740.
44. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009; 200: 1216-1226.
45. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health 2006; 6: 170.